[1] Gentile LF,Cuenca AG,Efron PA,et al.Persistent inflammation and immuno suppression:a common syndrome and new horizon for surgical intensive care [J].Trauma Acute Care Surg,2012,72(6):1491-1501.[2] Dellinger RP,Levy MM,Carlet JM,et al.Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock [J].Crit Care Med,2008,36(1):296-327.[3] WaD,Meydani SN.Age-associated change in immune and inflammatory responses:impact of vitamin E intervention [J].J Leukoc Biol,2008,84(4):900-914.[4] Hotchkiss RS,Opal S.Immunotherapy for sepsis:a new approach against an ancient foe[J].N Engl J Med,2010,363(1):87-89.[5] 董宁,姚永明,曹玉珏,等.大面积烧伤脓毒症患者T淋巴细胞免疫功能的改变及临床意义[J].中华烧伤杂志,2007,23(2):84-87.[6] Osuchowski MF,Welch K,Siddiqui J,etal.Circulationg cytokine/inhibitor profiles reshape the understanding of the sirs/cars continuum in sepsis and predict mortality [J].J Immunol,2006,177(3):1967-1974.[7] Huang LF,Yao Yin,Dong N,et al.Association between regulatory T cell activity and sepsis and outcome of severely burned patients:a prospective,observational study [J].Crit Care,2010,14(1):1-10.[8] Fehervati Z,Sakaguchi S.CD4+ Treg and immune control [J].J Clin Invest,2004,114(9):1209-1217.[9] 邵敏,刘宝,王锦树,等.脓毒症患者辅助性T细胞17和CD4+ CD5+调节性T细胞表述及血必净注射液的干预作用[J].中国危重症急救医学,2011,23(7):430-434.[10] 刘大为.实用重症医学[M].北京:人民卫生出版社,2010:321-323.[11] Kumpf O,Schumann RR.Genetic variation in innate immunity pathways and their potential contribution to the SIRS/CARS debate:Evidence from human studies and animal models[J].J Innate Immun,2010,2(5):381-394.[12] Hotchkiss RS,Karl LE.The pathophysiology and treatment of sepsis[J]. N Engl J Med,2003,348(2):138-150.[13] 刘景全,马国光,石斌,等.脓毒症大鼠小肠上皮PepT1的表达变化及其与Ghrelin的相关性研究[J].解放军医学杂志,2013,38(9):729-733.[14] 刘丽平,郭鸿,尹超,等.罗格列酮对脓毒症大鼠空肠短肽载体的调控机制研究[J].解放军医学杂志,2013,38(7):557-560. |